Compare Abeona Therapeutics Inc (ABEO) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Expeditors International of Wshngtn Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Expeditors International of Wshngtn Inc trades at $164.43 (market cap $21.68B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 58.1× Abeona Therapeutics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EXPD | |
|---|---|---|
Market Cap | $373.32M | $21.68B |
Sector | Health | Industrials |
52-Week High | $7.23 | $167.57 |
52-Week Low | $4.17 | $111.37 |
Enterprise Value | $228.22M | $20.93B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EXPD trades at $165.74, down 1.09% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company shows consistent earnings beats, with Q1 2026 EPS of $1.71 surpassing expectations of $1.33. Revenue growth is steady, reaching $11.07B in 2025, while maintaining robust profitability with a net margin of 7.48% and ROE of 36.59%. Recent news highlights EXPD's resilience in transportation services amid industry challenges.
The stock presents a mixed outlook: strong fundamentals and technical momentum support upside potential, but valuation multiples like P/E of 26.77 suggest premium pricing. Risks include economic sensitivity and competitive pressures. Analyst consensus is cautious with 60.61% hold ratings, though price targets indicate limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
